Ratings Nightingale Health Oyj

Equities

HEALTH

FI4000490875

Market Closed - Nasdaq Helsinki Other stock markets 11:23:10 2024-05-15 am EDT			5-day change	1st Jan Change
1.6 ^EUR	-1.84%		-15.79%	+43.37%

Apr. 16	Finland’s Nightingale Health Plots US Expansion	MT
Apr. 16	Nightingale Health to Establish A Laboratory in the United States	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company's "enterprise value to sales" ratio is among the highest in the world.
Revenue estimates are regularly revised downwards for the current and coming years.
Most analysts recommend that the stock should be sold or reduced.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NIGHTINGALE HEALTH OYJ	+43.37%	106M		-
VEEVA SYSTEMS INC.	+9.80%	32.94B		C
PRO MEDICUS LIMITED	+21.53%	7.83B		C-
SECTRA AB	+36.69%	4.26B		B-
EVOLENT HEALTH, INC.	-28.70%	2.74B		C-
OMNICELL, INC.	-20.62%	1.39B		B
VERADIGM INC.	-28.50%	1.27B	-	C+
LUNIT INC.	-32.48%	1.17B		-
SIMULATIONS PLUS, INC.	+12.29%	988M		C
B-SOFT CO.,LTD.	-37.86%	884M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes